Gsk (GLAXF) Long-Term Investments (2009 - 2026)

Gsk's Long-Term Investments history runs 18 years deep, the most recent figure standing at $133.5 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 7.04% year-over-year to $133.5 million; the TTM figure through Mar 2026 stood at $133.5 million (up 7.04% YoY), while the FY2025 annual figure was $117.3 million, down 4.37% from the prior year.
• Long-Term Investments was $133.5 million for Q1 2026 at Gsk, up from $118.4 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $1.7 billion in Q4 2022 to a low of -$54.6 million in Q3 2024.
• Historically, Long-Term Investments has averaged $183.4 million across 5 years, with a median of $97.0 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments jumped 8160.88% in 2023, then plunged 157.44% in 2024.
• A 5-year view of Long-Term Investments shows it stood at $1.7 billion in 2022, then slumped by 96.03% to $68.3 million in 2023, then jumped by 80.5% to $123.2 million in 2024, then dropped by 3.92% to $118.4 million in 2025, then increased by 12.74% to $133.5 million in 2026.
• The last three Long-Term Investments figures came in at $133.5 million (Q1 2026), $118.4 million (Q4 2025), and $174.1 million (Q3 2025), per Business Quant data.